MedTrace Logo

Effects of Remimazolam and Ciprofol TIVA on PRAE in Pediatric Tonsillectomy and Adenoidectomy

NCT07118579 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 114

Last updated 2025-11-21

No results posted yet for this study

Summary

To observe the effects of remimazolam versus ciprofol TIVA on PRAE in pediatric tonsillectomy and adenoidectomy.

Conditions

  • Tonsillectomy With or Without Adenoidectomy

Interventions

DRUG

Remimazolam

remimazolam induction (0.3-0.5 mg/kg) + maintenance (1-3 mg/kg/h)

DRUG

Propofol

Anesthesia induction (2-3 mg/kg) + Anesthesia maintenance (6-10 mg/kg/h)

DRUG

Ciprofol

Anesthesia induction (0.4-0.5 mg/kg) + Anesthesia maintenance (0.8-1.2 mg/kg/h)

Sponsors & Collaborators

  • Tongji Hospital

    lead OTHER

Principal Investigators

  • Mujun Chang · Tongji Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-23
Primary Completion
2026-08-31
Completion
2026-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07118579 on ClinicalTrials.gov